PL374349A1 - Hcv fusion proteins with modified ns3 domains - Google Patents

Hcv fusion proteins with modified ns3 domains

Info

Publication number
PL374349A1
PL374349A1 PL03374349A PL37434903A PL374349A1 PL 374349 A1 PL374349 A1 PL 374349A1 PL 03374349 A PL03374349 A PL 03374349A PL 37434903 A PL37434903 A PL 37434903A PL 374349 A1 PL374349 A1 PL 374349A1
Authority
PL
Poland
Prior art keywords
domains
modified
fusion proteins
hcv fusion
hcv
Prior art date
Application number
PL03374349A
Other languages
Polish (pl)
Inventor
Michael Houghton
Original Assignee
Chiron Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corporation filed Critical Chiron Corporation
Publication of PL374349A1 publication Critical patent/PL374349A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/503—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses
    • C12N9/506—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses derived from RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PL03374349A 2002-07-02 2003-07-02 Hcv fusion proteins with modified ns3 domains PL374349A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39369402P 2002-07-02 2002-07-02
US39451002P 2002-07-08 2002-07-08

Publications (1)

Publication Number Publication Date
PL374349A1 true PL374349A1 (en) 2005-10-17

Family

ID=30118384

Family Applications (1)

Application Number Title Priority Date Filing Date
PL03374349A PL374349A1 (en) 2002-07-02 2003-07-02 Hcv fusion proteins with modified ns3 domains

Country Status (8)

Country Link
EP (1) EP1539809A4 (en)
JP (2) JP2005532064A (en)
CN (1) CN1678630A (en)
AU (1) AU2003248818A1 (en)
CA (1) CA2491508A1 (en)
PL (1) PL374349A1 (en)
RU (1) RU2005102484A (en)
WO (1) WO2004005473A2 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7491808B2 (en) * 2000-06-15 2009-02-17 Novartis Vaccines And Diagnostics, Inc. HCV non-structural protein mutants and uses thereof
CA2505611A1 (en) * 2002-10-25 2004-05-13 Chiron Corporation Activation of hcv-specific cells
US7439042B2 (en) 2002-12-16 2008-10-21 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
NZ551319A (en) * 2004-05-17 2010-07-30 Novartis Vaccines & Diagnostic Truncated Hepatitis C virus NS5 domain and fusion proteins comprising same
EP1799868B1 (en) * 2004-08-27 2012-01-18 Novartis Vaccines and Diagnostics, Inc. Hcv non-structural protein mutants and uses thereof
AU2011254055B2 (en) * 2004-10-18 2012-12-20 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
AU2005295317B2 (en) * 2004-10-18 2011-10-13 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
CA2618429A1 (en) * 2005-05-25 2007-03-22 Tripep Ab A hepatitis c virus non-structural ns3/4a fusion gene
ZA200804078B (en) * 2005-10-13 2009-09-30 Virexx Medical Corp Chimeric hepatitis C virus antigens for eliciting an immune response
GB0524408D0 (en) * 2005-11-30 2006-01-11 Glaxosmithkline Biolog Sa Vaccines
EP2357184B1 (en) 2006-03-23 2015-02-25 Novartis AG Imidazoquinoxaline compounds as immunomodulators
CA2661492A1 (en) * 2006-08-25 2008-02-28 Novartis Ag Hcv fusion polypeptides
JP2012503011A (en) 2008-09-19 2012-02-02 グローブイミューン，インコーポレイテッド Immunotherapy of chronic hepatitis C virus infection
WO2012038950A1 (en) 2010-09-20 2012-03-29 Ramot At Tel-Aviv University Ltd. Activatable toxin complexes comprising a cleavable inhibitory peptide
JP6859314B2 (en) * 2015-03-27 2021-04-14 オーソ−クリニカル・ダイアグノスティックス・インコーポレイテッドＯｒｔｈｏ−Ｃｌｉｎｉｃａｌ Ｄｉａｇｎｏｓｔｉｃｓ， Ｉｎｃ． HCV NS4A / Modified NS3 polypeptide and its use
CN106749672B (en) * 2016-11-18 2020-06-30 江西农业大学 Hepatitis C virus fusion antigen protein and application thereof
CN111153963B (en) * 2020-01-19 2021-08-10 华南理工大学 Anti-inflammatory pentapeptide, extraction and separation method thereof and application of anti-inflammatory pentapeptide in memory improvement

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0979867A3 (en) * 1993-11-04 2007-06-13 Innogenetics N.V. Immunodominant human T-cell epitopes of hepatitis C virus
CN1425027A (en) * 1999-11-24 2003-06-18 希龙公司 HCV non-structural polypeptide
WO2001090812A1 (en) * 2000-05-23 2001-11-29 Massachusetts Institute Of Technology Ultraviolet fluoride nonlinear devices

Also Published As

Publication number Publication date
EP1539809A4 (en) 2006-03-08
RU2005102484A (en) 2006-01-20
CN1678630A (en) 2005-10-05
EP1539809A2 (en) 2005-06-15
WO2004005473A2 (en) 2004-01-15
CA2491508A1 (en) 2004-01-15
AU2003248818A1 (en) 2004-01-23
JP2006265267A (en) 2006-10-05
JP2005532064A (en) 2005-10-27
WO2004005473A3 (en) 2004-04-01

Similar Documents

Publication Publication Date Title
IL166751A0 (en) Modified transferin-antibody fusion proteins
PL374349A1 (en) Hcv fusion proteins with modified ns3 domains
IL166750A0 (en) Modified transferrin fusion proteins
AU2003239365A8 (en) Recombinant glycosyltransferase fusion proteins
EP1663278A4 (en) Epo mimetic peptides and fusion proteins
EP1594530A4 (en) Albumin fusion proteins
AU2003279766A8 (en) Microfluidic protein crystallography
PL366621A1 (en) Core-glycosylated hcv envelope proteins
GB0208331D0 (en) Proteins
EP1575992A4 (en) Protein transducing domain/deaminase chimeric proteins, related compounds, and uses thereof
GB0209884D0 (en) Proteins
EP1765386A4 (en) Truncated hepatitis c virus ns5 domain and fusion proteins comprising same
GB0315248D0 (en) HCV regulated protein expression
EP1687327A4 (en) Novel heat shock protein 20-related polypeptides and uses therefor
IL172184A0 (en) Interferon gamma - like protein
GB0200689D0 (en) Fusion proteins
EP1487874A4 (en) Falp proteins
GB0212067D0 (en) Proteins
EP1409551A4 (en) Chimeric capsid proteins and uses thereof
AU2003270055A8 (en) Neurotransmission-associated proteins
AU2003300785A8 (en) Carbohydrate-associated proteins
AU2003236908A8 (en) Proteins
AU2003295760A8 (en) Organelle-associated proteins
GB0216757D0 (en) Proteins
GB0102678D0 (en) Combinatorial protein domains

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)